Of note, FGFR1 activity has also been implicated in MEK inhibitor resistance in KRAS-mutant NSCLC, where it activated MEK and AKT in MEK inhibitor-resistant cells, resulting in induction of epithelial-mesenchymal transition [35, 36]. Here, FGFR1 is linked to non-small cell lung carcinoma.